Cargando…
Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
BACKGROUND: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779995/ https://www.ncbi.nlm.nih.gov/pubmed/33124216 http://dx.doi.org/10.3947/ic.2020.52.4.516 |
_version_ | 1783631428700864512 |
---|---|
author | Kanchanasurakit, Sukrit Santimaleeworagun, Wichai McPherson, Charles E. Piriyachananusorn, Napacha Boonsong, Benjawan Katwilat, Papanin Saokaew, Surasak |
author_facet | Kanchanasurakit, Sukrit Santimaleeworagun, Wichai McPherson, Charles E. Piriyachananusorn, Napacha Boonsong, Benjawan Katwilat, Papanin Saokaew, Surasak |
author_sort | Kanchanasurakit, Sukrit |
collection | PubMed |
description | BACKGROUND: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC). MATERIALS AND METHODS: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation. RESULTS: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases). CONCLUSION: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed. |
format | Online Article Text |
id | pubmed-7779995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS |
record_format | MEDLINE/PubMed |
spelling | pubmed-77799952021-01-05 Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection Kanchanasurakit, Sukrit Santimaleeworagun, Wichai McPherson, Charles E. Piriyachananusorn, Napacha Boonsong, Benjawan Katwilat, Papanin Saokaew, Surasak Infect Chemother Original Article BACKGROUND: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC). MATERIALS AND METHODS: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation. RESULTS: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases). CONCLUSION: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed. The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2020-12 2020-10-26 /pmc/articles/PMC7779995/ /pubmed/33124216 http://dx.doi.org/10.3947/ic.2020.52.4.516 Text en Copyright © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kanchanasurakit, Sukrit Santimaleeworagun, Wichai McPherson, Charles E. Piriyachananusorn, Napacha Boonsong, Benjawan Katwilat, Papanin Saokaew, Surasak Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection |
title | Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection |
title_full | Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection |
title_fullStr | Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection |
title_full_unstemmed | Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection |
title_short | Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection |
title_sort | fosfomycin dosing regimens based on monte carlo simulation for treated carbapenem-resistant enterobacteriaceae infection |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779995/ https://www.ncbi.nlm.nih.gov/pubmed/33124216 http://dx.doi.org/10.3947/ic.2020.52.4.516 |
work_keys_str_mv | AT kanchanasurakitsukrit fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection AT santimaleeworagunwichai fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection AT mcphersoncharlese fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection AT piriyachananusornnapacha fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection AT boonsongbenjawan fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection AT katwilatpapanin fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection AT saokaewsurasak fosfomycindosingregimensbasedonmontecarlosimulationfortreatedcarbapenemresistantenterobacteriaceaeinfection |